Cogent Biosciences, Inc. financial data

Symbol
COGT on Nasdaq
Location
Waltham, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 07 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 528% % -38%
Debt-to-equity 41% % 136%
Return On Equity -126% % -78%
Return On Assets -90% % -48%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 142,376,529 shares 29%
Common Stock, Shares, Outstanding 139,827,662 shares 27%
Entity Public Float $869,300,000 USD -10%
Common Stock, Value, Issued $141,000 USD 28%
Weighted Average Number of Shares Outstanding, Basic 137,550,159 shares 25%
Weighted Average Number of Shares Outstanding, Diluted 137,550,159 shares 25%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $256,266,000 USD 17%
General and Administrative Expense $51,338,000 USD 25%
Costs and Expenses $307,604,000 USD 18%
Operating Income (Loss) $307,604,000 USD -18%
Nonoperating Income (Expense) $13,232,000 USD -27%
Net Income (Loss) Attributable to Parent $294,372,000 USD -21%
Earnings Per Share, Basic -2 USD/shares -28%
Earnings Per Share, Diluted -2 USD/shares -28%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $125,297,000 USD 29%
Assets, Current $397,244,000 USD 16%
Property, Plant and Equipment, Net $5,274,000 USD -25%
Operating Lease, Right-of-Use Asset $18,591,000 USD -9.7%
Other Assets, Noncurrent $4,488,000 USD -7.7%
Assets $425,933,000 USD 11%
Accounts Payable, Current $16,029,000 USD 6.4%
Employee-related Liabilities, Current $10,498,000 USD 36%
Liabilities, Current $62,246,000 USD 17%
Operating Lease, Liability, Noncurrent $14,603,000 USD -10%
Other Liabilities, Noncurrent $2,370,000 USD
Liabilities $123,469,000 USD 78%
Accumulated Other Comprehensive Income (Loss), Net of Tax $208,000 USD -77%
Retained Earnings (Accumulated Deficit) $1,085,928,000 USD -37%
Stockholders' Equity Attributable to Parent $302,464,000 USD -3.9%
Liabilities and Equity $425,933,000 USD 11%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $66,511,000 USD -27%
Net Cash Provided by (Used in) Financing Activities $24,970,000 USD -88%
Net Cash Provided by (Used in) Investing Activities $69,379,000 USD 6545%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 139,827,662 shares 27%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $27,838,000 USD -83%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $125,633,000 USD 29%
Deferred Tax Assets, Valuation Allowance $218,552,000 USD 39%
Operating Lease, Liability $17,467,000 USD -7.4%
Payments to Acquire Property, Plant, and Equipment $547,000 USD 681%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $295,060,000 USD -22%
Lessee, Operating Lease, Liability, to be Paid $25,234,000 USD -9.9%
Property, Plant and Equipment, Gross $12,582,000 USD 4.8%
Operating Lease, Liability, Current $1,706,000 USD 12%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,697,000 USD -5.1%
Lessee, Operating Lease, Liability, to be Paid, Year One $2,841,000 USD 2.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $7,767,000 USD -15%
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,132,000 USD -21%
Deferred Tax Assets, Operating Loss Carryforwards $64,299,000 USD 34%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $2,179,000 USD 2.2%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $40,305,000 USD 4.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%